MedPath

ROSWELL PARK CANCER INSTITUTE

πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors

Phase 1
Completed
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
First Posted Date
2003-06-20
Last Posted Date
2011-03-07
Lead Sponsor
Roswell Park Cancer Institute
Registration Number
NCT00024141
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors

Phase 2
Completed
Conditions
Breast Cancer
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Testicular Germ Cell Tumor
Unspecified Adult Solid Tumor, Protocol Specific
Unspecified Childhood Solid Tumor, Protocol Specific
First Posted Date
2003-05-07
Last Posted Date
2013-05-09
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
451
Registration Number
NCT00060255
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

Photodynamic Therapy Using HPPH in Treating Patients With Obstructive Esophageal Tumors

Phase 1
Completed
Conditions
Esophageal Cancer
First Posted Date
2003-05-07
Last Posted Date
2011-03-09
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
11
Registration Number
NCT00060268
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

Phase 3
Completed
Conditions
Leukemia
First Posted Date
2003-04-16
Last Posted Date
2012-04-13
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
61
Registration Number
NCT00002945
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

Interleukin-2 and Stem Cell Factor in Treating Patients With AIDS or AIDS-Related Cancer

Phase 1
Completed
Conditions
Lymphoma
First Posted Date
2003-04-09
Last Posted Date
2013-01-31
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
1
Registration Number
NCT00058045
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

πŸ‡ΊπŸ‡Έ

Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States

Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery

Phase 2
Completed
Conditions
Lung Cancer
First Posted Date
2003-04-09
Last Posted Date
2011-03-08
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
21
Registration Number
NCT00057798
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

Compassionate Use of Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Gastrointestinal Tract

Not Applicable
Completed
Conditions
Graft Versus Host Disease
First Posted Date
2003-03-07
Last Posted Date
2011-03-08
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
51
Registration Number
NCT00055666
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Phase 2
Completed
Conditions
Leukemia
Lymphoma
Myelodysplastic Syndromes
Myelodysplastic-Myeloproliferative Diseases
First Posted Date
2003-03-07
Last Posted Date
2011-03-07
Lead Sponsor
Roswell Park Cancer Institute
Registration Number
NCT00055653
Locations
πŸ‡ΊπŸ‡Έ

City of Hope Comprehensive Cancer Center, Duarte, California, United States

πŸ‡ΊπŸ‡Έ

Children's Hospital Los Angeles, Los Angeles, California, United States

πŸ‡ΊπŸ‡Έ

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

and more 22 locations

Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors

Phase 1
Completed
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
First Posted Date
2003-02-06
Last Posted Date
2014-01-13
Lead Sponsor
Roswell Park Cancer Institute
Registration Number
NCT00054288
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma

Phase 2
Completed
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
First Posted Date
2003-02-06
Last Posted Date
2022-10-03
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
24
Registration Number
NCT00054158
Locations
πŸ‡ΊπŸ‡Έ

Roswell Park Cancer Institute, Buffalo, New York, United States

Β© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy